Publication: new SRA737 combinations in cancer

RNS Number : 8364F
Sareum Holdings PLC
12 March 2020


12 March 2020

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014

Sareum Holdings plc

("Sareum" or the "Company")

Sareum notes publication of new research highlighting the therapeutic potential of SRA737 in a new drug combination targeting lung and colorectal cancers

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes a new publication in the leading peer-reviewed journal, Cancer Research (an official publication of the American Association of Cancer Research; AACR), describing the anti-cancer effect of the CHK1 inhibitor, SRA737, in multiple human lung and colorectal cancer cells, when used in combination with small molecules that block the function of a family of proteins involved in DNA replication and repair (B-family DNA polymerases). This new approach was reported by researchers at the Institute of Cancer Research ("ICR") and the University of Kent, who were investigating drug combinations involving SRA737 that act synergistically to kill cancer cells and that could form the basis of further research and development programmes.

SRA737 was discovered and initially developed by scientists at ICR in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 is licensed to Nasdaq-listed Sierra Oncology Inc. ("Sierra") and has demonstrated positive safety and efficacy in combination with low-dose gemcitabine from a Phase 1/2 clinical development programme supporting standalone development in anogenital cancer. This programme is ongoing, with Sierra seeking to on-license SRA737 for further development.

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London and co-leader for the study, said:

"Our new study establishes the basis for a potentially exciting new approach to treatment involving a two-pronged attack on cancer. We found that doubling up on drugs that target the systems for repairing DNA could be effective even against cancers that do not respond to single-drug treatment.

"Our findings also provide us with a way of picking out which patients are most likely to benefit from existing CHK1 inhibitors like SRA737."

Sareum's Chief Scientific Officer, Dr John Reader, commented:

"These new data add to the growing evidence supporting the potential of combination approaches to cancer therapy, using SRA737 with other molecules that are crucial to the DNA replication and repair mechanism. The research published today, alongside the very promising clinical and preclinical data reported by Sierra, continues to suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined cancer patients."

The full announcement on the new publication from the ICR can be found in the News section of the ICR website   


R.F. Rogers et al. CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells. (2020) Cancer Research

To read the paper, please follow:
DOI number: 10.1158/008-5472.CAN-19-1372

For further information, please contact: 

Sareum Holdings plc


Tim Mitchell

01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / Richard Tulloch

020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce / John Beresford-Peirse

020 3764 2341

Citigate Dewe Rogerson (Media enquiries)

Mark Swallow / David Dible

020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune disease. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases (SDC-1801) and cancers (SDC-1802). The Company is targeting first human clinical trials in each indication in 2020.

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (CHK1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients. SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology, in a $328.5m plus royalties licence deal, with Sareum eligible to receive 27.5% of all payments to CPF under the agreement.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
UK 100